Post-marketing safety surveillance of tarlatamab: a real-world pharmacovigilance study based on the FAERS database

Key Points

• Adverse events associated with tarlatamab were detailed in the FAERS database, indicating safety concerns.
• The analysis identified specific adverse events, emphasizing the importance of real-world evidence in post-marketing studies.
• Pharmacovigilance efforts utilized the FAERS database to assess the safety profile of tarlatamab in a clinical setting.
• These findings highlight ongoing safety surveillance needs to ensure patient safety with tarlatamab.